{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:26:25Z","timestamp":1789698385955,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82071967, 82202218"],"award-info":[{"award-number":["No. 82071967, 82202218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["XH-QN-012K, 2022-PUMCH-D-001, 2022-PUMCH-B-072"],"award-info":[{"award-number":["XH-QN-012K, 2022-PUMCH-D-001, 2022-PUMCH-B-072"]}]},{"name":"CAMS innovation fund for medical science","award":["No. CIFMS-2021-I2M-1-025, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003"],"award-info":[{"award-number":["No. CIFMS-2021-I2M-1-025, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003"]}]},{"name":"National Key Research and Development Program of China","award":["No. 2016YFC0901500"],"award-info":[{"award-number":["No. 2016YFC0901500"]}]},{"name":"CAMS fund for Rare Diseases Research","award":["No. 2016ZX310174-4"],"award-info":[{"award-number":["No. 2016ZX310174-4"]}]},{"name":"Tsinghua university and PUMCH joint fund","award":["No. PTQH201906006"],"award-info":[{"award-number":["No. PTQH201906006"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["A1258300"],"award-info":[{"award-number":["A1258300"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00259-024-06790-y","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T04:02:03Z","timestamp":1718424123000},"page":"3719-3730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial"],"prefix":"10.1007","volume":"51","author":[{"given":"Meixi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-083X","authenticated-orcid":false,"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"6","key":"6790_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11912-022-01217-z","volume":"24","author":"EN Rizen","year":"2022","unstructured":"Rizen EN, Phan AT. Neuroendocrine tumors: a relevant Clinical Update. Curr Oncol Rep. 2022;24(6):703\u201314.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"6790_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228\u201352.","journal-title":"Front Neuroendocrinol"},{"issue":"11","key":"6790_CR3","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.3390\/cimb44110373","volume":"44","author":"G Poletto","year":"2022","unstructured":"Poletto G, Cecchin D, Sperti S, Filippi L, Realdon N, Evangelista L. Head-to-Head comparison between peptide-based Radiopharmaceutical for PET and SPECT in the evaluation of neuroendocrine tumors: a systematic review. Curr Issues Mol Biol. 2022;44(11):5516\u201330.","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"6790_CR4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.122.264890","volume":"64","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zhu W, Zhang J, Miao W, Yao S, Huo L. Head-to-Head comparison of (68)Ga-NODAGA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: interim analysis of a prospective Bicenter Study. J Nucl Med. 2023;64(9):1406\u201311.","journal-title":"J Nucl Med"},{"issue":"6","key":"6790_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al. Sensitivity comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915\u201321.","journal-title":"J Nucl Med"},{"issue":"6","key":"6790_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2967\/jnumed.119.235093","volume":"61","author":"W Zhu","year":"2020","unstructured":"Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-Head comparison of (68)Ga-DOTA-JR11 and (68)Ga-DOTATATE PET\/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897\u2013903.","journal-title":"J Nucl Med"},{"issue":"5","key":"6790_CR7","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00259-021-05512-y","volume":"49","author":"W Zhu","year":"2022","unstructured":"Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with (68)Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49(5):1613\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6790_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2967\/jnumed.123.265622","volume":"64","author":"H Leupe","year":"2023","unstructured":"Leupe H, Ahenkorah S, Dekervel J, Unterrainer M, Van Cutsem E, Verslype C, et al. (18)F-Labeled somatostatin analogs as PET Tracers for the somatostatin receptor: ready for clinical use. J Nucl Med. 2023;64(6):835\u201341.","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"6790_CR9","doi-asserted-by":"publisher","first-page":"s61","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and therapy. J Nucl Med. 2017;58(Suppl 2):s61\u20136.","journal-title":"J Nucl Med"},{"key":"6790_CR10","doi-asserted-by":"crossref","unstructured":"Liu M, Cheng Y, Bai C, Zhao H, Jia R, Chen J et al. Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. Eur J Nucl Med Mol Imaging 2024.","DOI":"10.1007\/s00259-024-06639-4"},{"issue":"10","key":"6790_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/RLU.0000000000004757","volume":"48","author":"J Yang","year":"2023","unstructured":"Yang J, Deng J, Fan D, Chen G, Lu Z, Liu H, et al. Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET imaging for patients with bone metastases. Clin Nucl Med. 2023;48(10):847\u201352.","journal-title":"Clin Nucl Med"},{"key":"6790_CR12","doi-asserted-by":"crossref","unstructured":"Ahenkorah S, Cawthorne C, Murce E, Deroose CM, Cardinaels T, Seimbille Y et al. Direct comparison of [(18)F]AlF-NOTA-JR11 and [(18)F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: antagonist versus agonist. Nucl Med Biol 2023;118\u20139:108338.","DOI":"10.1016\/j.nucmedbio.2023.108338"},{"key":"6790_CR13","doi-asserted-by":"crossref","unstructured":"Dam JH, Langkj\u00e6r N, Baun C, Olsen BB, Nielsen AY, Thisgaard H. Preparation and evaluation of [(18)F]AlF-NOTA-NOC for PET imaging of neuroendocrine tumors: comparison to [(68)Ga]Ga-DOTA\/NOTA-NOC. Molecules 2022;27 (20).","DOI":"10.3390\/molecules27206818"},{"issue":"4","key":"6790_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.122.264563","volume":"64","author":"E Pauwels","year":"2023","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, et al. (18)F-AlF-NOTA-Octreotide outperforms (68)Ga-DOTATATE\/NOC PET in neuroendocrine tumor patients: results from a prospective, Multicenter Study. J Nucl Med. 2023;64(4):632\u20138.","journal-title":"J Nucl Med"},{"issue":"10","key":"6790_CR15","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","volume":"48","author":"Q Xie","year":"2021","unstructured":"Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [(18)F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [(68)Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6790_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.30773\/pi.2017.08.17","volume":"15","author":"HG Kim","year":"2018","unstructured":"Kim HG, Cheon EJ, Bai DS, Lee YH, Koo BH. Stress and heart rate variability: a Meta-analysis and review of the literature. Psychiatry Investig. 2018;15(3):235\u201345.","journal-title":"Psychiatry Investig"},{"issue":"13","key":"6790_CR17","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00259-020-04918-4","volume":"47","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3033\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6790_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2967\/jnumed.115.169532","volume":"57","author":"SR Dubash","year":"2016","unstructured":"Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, et al. Clinical translation of a click-labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine tumors. J Nucl Med. 2016;57(8):1207\u201313.","journal-title":"J Nucl Med"},{"key":"6790_CR19","doi-asserted-by":"crossref","unstructured":"Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N et al. Al[(18)F]F-NOTA-Octreotide is comparable to [(68)Ga]Ga-DOTA-TATE for PET\/CT Imaging of Neuroendocrine Tumours in the Latin-American Population. Cancers (Basel) 2023;15 (2).","DOI":"10.3390\/cancers15020439"},{"issue":"11","key":"6790_CR20","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00259-019-04425-1","volume":"46","author":"E Pauwels","year":"2019","unstructured":"Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. Al(18)F-NOTA-octreotide: first comparison with (68)Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging. 2019;46(11):2398\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"6790_CR21","first-page":"566","volume":"47","author":"G Meisetschl\u00e4ger","year":"2006","unstructured":"Meisetschl\u00e4ger G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med. 2006;47(4):566\u201373.","journal-title":"J Nucl Med"},{"issue":"3","key":"6790_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/153303460700600309","volume":"6","author":"MD Seemann","year":"2007","unstructured":"Seemann MD. Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18F-TOCA PET, triple-phase CT, and PET\/CT. Technol Cancer Res Treat. 2007;6(3):213\u201320.","journal-title":"Technol Cancer Res Treat"},{"issue":"2","key":"6790_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00259-007-0576-1","volume":"35","author":"H Wieder","year":"2008","unstructured":"Wieder H, Beer AJ, Poethko T, Meisetschlaeger G, Wester HJ, Rummeny E, et al. PET\/CT with gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging. 2008;35(2):264\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6790_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2967\/jnumed.123.266601","volume":"65","author":"S Dubash","year":"2024","unstructured":"Dubash S, Barwick TD, Kozlowski K, Rockall AG, Khan S, Khan S, et al. Somatostatin receptor imaging with [(18)F]FET-\u03b2AG-TOCA PET\/CT and [(68)Ga]Ga-DOTA-Peptide PET\/CT in patients with neuroendocrine tumors: a prospective, phase 2 comparative study. J Nucl Med. 2024;65(3):416\u201322.","journal-title":"J Nucl Med"},{"issue":"1","key":"6790_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13550-021-00797-4","volume":"11","author":"J Hou","year":"2021","unstructured":"Hou J, Long T, He Z, Zhou M, Yang N, Chen D, et al. Evaluation of (18)F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with (68)Ga-DOTATATE PET\/CT. EJNMMI Res. 2021;11(1):55.","journal-title":"EJNMMI Res"},{"issue":"6","key":"6790_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11307-021-01628-7","volume":"23","author":"J Hou","year":"2021","unstructured":"Hou J, Long T, Yang N, Chen D, Zeng S, Zheng K, et al. Biodistribution of (18)F-AlF-NOTA-octreotide in different organs and characterization of Uptake in Neuroendocrine neoplasms. Mol Imaging Biol. 2021;23(6):827\u201335.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"6790_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41181-019-0084-1","volume":"5","author":"T Tshibangu","year":"2020","unstructured":"Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, et al. Automated GMP compliant production of [(18)F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5(1):4.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"6790_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00259-019-04501-6","volume":"47","author":"H Ilhan","year":"2020","unstructured":"Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6790_CR29","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1007\/s00259-019-04448-8","volume":"46","author":"H Ilhan","year":"2019","unstructured":"Ilhan H, Todica A, Lindner S, Boening G, Gosewisch A, W\u00e4ngler C, et al. First-in-human (18)F-SiFAlin-TATE PET\/CT for NET imaging and theranostics. Eur J Nucl Med Mol Imaging. 2019;46(11):2400\u20131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6790_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nucmedbio.2020.07.008","volume":"88\u201389","author":"S Lindner","year":"2020","unstructured":"Lindner S, Simmet M, Gildehaus FJ, Jurkschat K, W\u00e4ngler C, W\u00e4ngler B, et al. Automated production of [(18)F]SiTATE on a Scintomics GRP\u2122 platform for PET\/CT imaging of neuroendocrine tumors. Nucl Med Biol. 2020;88\u201389:86\u201395.","journal-title":"Nucl Med Biol"},{"issue":"3","key":"6790_CR31","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1097\/RLU.0000000000002906","volume":"45","author":"J Zhang","year":"2020","unstructured":"Zhang J, Kulkarni HR, Singh A, Baum RP. Successful intra-arterial peptide receptor Radionuclide Therapy of DOTATOC-Negative high-Grade Liver metastases of a pancreatic neuroendocrine neoplasm using 177Lu-DOTA-LM3: a somatostatin receptor antagonist. Clin Nucl Med. 2020;45(3):e165\u20138.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"6790_CR32","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","volume":"62","author":"RP Baum","year":"2021","unstructured":"Baum RP, Zhang J, Schuchardt C, M\u00fcller D, M\u00e4cke H. First-in-humans study of the SSTR antagonist (177)Lu-DOTA-LM3 for peptide receptor Radionuclide Therapy in patients with metastatic neuroendocrine neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021;62(11):1571\u201381.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06790-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:28:21Z","timestamp":1727760501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06790-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6790"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06790-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with with the principles of the Helsinki Declaration. The study was approved by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images in all figures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}